| 产品名称 |
Recombinant Human CLDN18.2 (N-Twin strep-Flag) |
| 英文名称 |
CLDN18.2/Claudin 18.2 |
| 纯度 |
Greater than 95% as determined by reducing SDS-PAGE |
| 内毒素 |
<1 EU/µg as determined by LAL test. |
| 蛋白构建 |
Recombinant Human CLDN18.2 is produced by our Mammalian expression system and the target gene encoding Met1-Ala200 is expressed with a Twin strep, Flag tag at the N-terminus.The product is not recommended for cell based experiments. *The product is not recommended for cell based experiments. |
| Accession |
P56856-2 |
| 表达宿主 |
Human cells |
| 种属 |
Human |
| 预测分子量 |
25.5 kDa |
| 制剂 |
Supplied as a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, 0.06% DDM, 0.012% CHS, 10% Glycerol, pH 7.5. |
| 运输方式 |
The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| 稳定性&储存 |
Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
| 复溶 |
| 分子别名 |
| Claudin-18.2; CLDN18.2; CLDN18; Claudin-18; Claudin 18.2 |
| 背景介绍 |
| Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas，while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
注意事项
本司产品仅用于科研，不用于临床诊断和治疗
